文献速递消化内镜消化道出血

不间断氯吡格雷治疗下结肠息肉切除术后出血风险:一项独立于业界的双盲随机试验

Risk of Postpolypectomy Bleeding With Uninterrupted Clopidogrel Therapy in an Industry-Independent, Double-Blind, Randomized Trial.
PubMed 文献 · Gastroenterology · 2018-10-25

该双盲随机试验纳入香港2012年2月28日至2018年4月11日因心血管疾病服用氯吡格雷并接受择期结肠镜检查的患者,随机分为结肠镜检查前每日服用氯吡格雷75 mg组或安慰剂组。息肉切除患者中氯吡格雷组延迟性息肉切除术后出血累积发生率为3.8%,安慰剂组为3.6%,差异无统计学意义(P=.945)。

要点

  • 息肉切除患者中氯吡格雷组延迟性出血累积发生率为3.8%,安慰剂组为3.6%,差异无统计学意义(P=.945)。
  • 即刻息肉切除术后出血氯吡格雷组8.5% vs 安慰剂组5.5%,差异无统计学意义(P=.380)。
  • 严重心血管血栓事件氯吡格雷组1.5% vs 安慰剂组2%,差异无统计学意义(P=.713)。

核心结论

  • 在服用氯吡格雷并接受结肠镜检查的随机对照试验中,继续服用氯吡格雷的患者发生延迟性和即刻息肉切除术后出血的比例略高,但差异无统计学意义。

研究设计与样本

  • 研究为独立于业界的双盲随机对照试验,纳入香港2012年2月28日至2018年4月11日因心血管疾病服用氯吡格雷并接受择期结肠镜检查的患者;合格患者被指示在结肠镜检查前7天停用氯吡格雷,随后随机分配至每日服用氯吡格雷75 mg组或安慰剂组直至结肠镜检查当日早晨,结肠镜检查后所有患者恢复常规氯吡格雷处方。
  • 共387例患者接受结肠镜检查,其中216例需要息肉切除(氯吡格雷组106例,安慰剂组110例)。
  • 主要终点为结肠镜检查后30天内需要住院或干预的延迟性息肉切除术后出血;次要终点为即刻息肉切除术后出血和结肠镜检查后长达6个月的严重心血管血栓事件(依据抗血栓试验者标准);所有事件由独立盲法委员会裁定。

主要发现

  • 延迟性息肉切除术后出血累积发生率氯吡格雷组为3.8%(95%CI 1.4-9.7),安慰剂组为3.6%(95%CI 1.4-9.4),log-rank检验P=.945。
  • 即刻息肉切除术后出血氯吡格雷组为8.5%,安慰剂组为5.5%,P=.380,差异无统计学意义。
  • 心血管血栓事件氯吡格雷组为1.5%,安慰剂组为2%,P=.713,差异无统计学意义。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Guidelines recommend withholding clopidogrel 7 days before polypectomy to decrease bleeding risk, but these were written based on limited evidence. We investigated whether uninterrupted clopidogrel therapy increases the risk of delayed postpolypectomy bleeding in patients undergoing colonoscopy. METHODS: We identified patients receiving clopidogrel for cardiovascular disease undergoing elective colonoscopies in Hong Kong from February 28, 2012 through April 11, 2018. Eligible patients were instructed to stop taking clopidogrel 7 days before colonoscopy. Then, they were randomly assigned to groups given clopidogrel (75 mg) or placebo daily until the morning of colonoscopy. All patients resumed their usual prescriptions of clopidogrel after colonoscopy. The primary end point was delayed postpolypectomy bleeding that required hospitalization or intervention up to 30 days after colonoscopy. Secondary end points were immediate postpolypectomy bleeding and serious cardio-thrombotic events for as long as 6 months after colonoscopy, according to Antithrombotic Trialists' criteria. All events were adjudicated by an independent masked committee. RESULTS: In total, 387 patients underwent colonoscopy and 216 required polypectomies (106 patients in the clopidogrel group and 110 patients in the placebo group). The cumulative incidence of delayed postpolypectomy bleeding was 3.8% (95% confidence interval 1.4-9.7) in the clopidogrel group and 3.6% (95% confidence interval 1.4-9.4) in the placebo group (P = .945 by log-rank test). There were no significant differences in immediate postpolypectomy bleeding (8.5% vs 5.5%; P = .380) and cardio-thrombotic events (1.5% vs 2%; P = .713). CONCLUSIONS: In a randomized controlled trial of clopidogrel users undergoing colonoscopy, a slightly larger proportion of patients continuing clopidogrel developed delayed and immediate postpolypectomy bleeding, although this difference was not statistically significant. ClinicalTrials.gov, number NCT01806090.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Chan FKL, Kyaw MH, Hsiang JC, et al. Risk of Postpolypectomy Bleeding With Uninterrupted Clopidogrel Therapy in an Industry-Independent, Double-Blind, Randomized Trial. Gastroenterology. 2018. PMID: 30518511. doi:10.1053/j.gastro.2018.10.036

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。